1.39k followers • 11 symbols Watchlist by Yahoo Finance
This basket consists of stocks that benefit from the needs of aging baby boomers.
Allergan Plc on Friday agreed to split its chairman and chief executive roles, but only at its next leadership change, as the drugmaker pushed back against claims from activist hedge fund Appaloosa LP that an independent chair could help current CEO Brent Saunders boost the company's sagging share price. Saunders, 49, put together the current version of Allergan through a series of deals to roll up several pharmaceutical companies in 2014, and has run the company since then. Appaloosa, led by billionaire hedge fund manager David Tepper, has been agitating for changes at Allergan since last year as Allergan's shares have sagged.
Allergan Plc said on Friday its board chairman shall be an independent member, starting with the next leadership transition. Hedge fund Appaloosa LP, led by billionaire David Tepper, had been repeatedly ...
Long-term income investors know that finding dividend stocks with decades of interrupted payments is only part of the winning formula for income investing. Dividend growth matters, too - which is exactly why investors cherish the Dividend Aristocrats.Dividend Aristocrats are companies in the Standard & Poor's 500-stock index that have hiked their dividends every year for at least 25 consecutive years. Rising dividends naturally make these stocks more attractive to new income investors, and steady payout hikes reward existing investors with increasingly higher yields on their shares' original buy-in cost.Most importantly, regular dividend hikes fuel the magic of compounding. Indeed, many of the best stocks of all time have long histories of dividend growth.Since reliable dividend stocks with growing payouts can provide some comfort amid market uncertainty, we took a look at the 11 Dividend Aristocrats with the longest histories of annual dividend increases. After all, when a dividend stock manages to raise its payout through good times and bad, decade after decade, you know management is making its income-reliant shareholders a top priority. SEE ALSO: The Kiplinger Dividend 15: Our Favorite Dividend-Paying Stocks
A new Procter & Gamble Co. advertisement seeks to promote more than just a brand. The commercial advocates equal pay for women.
Cannabidiol (CBD) is emerging as a red-hot category of the marijuana industry. CBD includes compounds in the cannabis sativa plant that do not produce a high. In fact, over the years, CBDs have been shown to have powerful therapeutic effects.Now it looks like the U.S. market could open up in a big way for this type of cannabis and several CBD stocks are gaining traction. The reason: In December, Congress passed the 2018 Farm Bill, which declared that CBD would no longer be treated as an illegal substance.So how big could this opportunity be? Well, according to research from the Brightfield Group, the market in the U.S. could hit $22 billion by 2022.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The 10 Best ETFs to Buy in the Second Quarter No doubt, this could move the needle for marijuana stocks -- and here's a look at seven that stand out: Cronos Group (CRON)Cronos Group (NYSE:CRON) operates a vertically integrated cannabis platform, with a presence across five continents. In terms of the CBD opportunity, the company recently struck a strategic partnership with Gingko Bioworks, which has raised $430 million. The company's founder, Tom Knight, is known as the "father of synthetic biology" and his innovations -- such as with software to print DNA -- should allow for the creation of cannabinoids at a massive scale. This is critical because it can be difficult to produce pure forms that are cost-effective and precise.CRON also has the advantage of substantial financial resources to commercialize its cannabinoids. Last December, Altria (NYSE:MO) invested $1.8 billion into the company for a 45% stake. The deal is certainly a validation of CRON but it will also allow for much broader distribution and improved product development.Of course, a company like MO does engage in substantial due diligence before making an investment. In the latest earnings call, CEO Howard Willard said: "We believe the growth opportunities are significant and will extend across the globe as cannabis markets open. Selecting the right partner in this category was critical and we've done just that. Cronos strong management team has built unique capabilities to compete globally across the medicinal, recreational and nutraceutical categories." Aurora Cannabis (ACB)Aurora Cannabis (NYSE:ACB), a Canadian based cannabis producer, has been building up its CBD business. Part of this has been with its investments in industrial hemp production, such as with the Radient facility in Edmonton. It is expected to get as much as 10,000 kilos per day.Next, ACB has been focused on revving up its product offerings. According to the latest earnings call, Chief Corporate Officer Cam Battley, the company is poised "to launch a broad line of CBD based wellness product in the near future."What's more, ACB has been aggressive with its dealmaking. For example, it has increased its equity position in Hempco and purchased Agropro, which is Europe's largest hemp producer. * 10 Stocks on the Rise Heading Into the Second Quarter Something else to keep in mind: Legendary billionaire investor Nelson Peltz has joined the company as an advisor. This is certainly a major vote of confidence. He not only has deep access to investment capital but a strong network of potential partners, especially in the consumer goods industry. Some of his investments include stakes in PepsiCo (NASDAQ:PEP), Procter & Gamble (NYSE:PG) and Mondelez (NASDAQ:MDLZ). Charlotte's Web (CWBHF)The inspiration for the founding of Charlotte's Web (OTCMKTS:CWBHF) was a CNN documentary -- in 2013 -- about Charlotte Figi, whose health was significantly improved because of a hemp extract.Fast forward to today: The company is the No. 1 brand for the hemp-derived CBD market in the U.S. It definitely helps that it has distribution across more than 3,000 retail locations.And yes, growth has been strong. In the latest quarter, revenues jumped by 57% to $17.7 million and adjusted EBITDA came to $5.4 million, up 31%.To better capitalize on the CBD opportunity, CWBHF recently issued $71.5 million in stock. This will be for cultivation and production to meet surging demand. Here's what the company's CEO, Hess Moallem, had to say: "In general, broader consumer awareness of the benefits of cannabinoids, namely cannabidiol (CBD), and whole plant hemp extract is driving increased uptake in both our retail channels and within our e-commerce platform."In other words, it seems like a pretty good bet that the growth will continue for some time. Zynerba Pharmaceuticals (ZYNE)Zynerba Pharmaceuticals (NASDAQ:ZYNE) is a clinical-stage biotech company that develops cannabinoid therapies for a variety of rare diseases. They include: * Fragile X Syndrome (FXS): This is a developmental disability that has been known to cause autism spectrum disorder. FXS impacts 71,000 people in the U.S. and there are no drug indications for it. * Developmental and Epileptic Encephalopathies (DEE): This is an epilepsy syndrome that involves severe cognitive impairment. About 45,000 children and adolescents have this in the U.S. * Autism Spectrum Disorder (ASD): This includes autism and Asperger's syndrome. ASD affects less than 1 million pediatric and adolescent patients. * 7 Retail Stocks That Will Continue to Rebound in 2019 ZYNE's main candidate is Zygel, which is a CBD formulation gel for transdermal delivery. As for the FXS treatment, there is expected to be a pivotal data release in the second half of this year. And if the trial is positive, then the company will file a New Drug Application (NDA) for Zygel in the first half of 2020. Canopy Growth (CGC)Since 2016, Canopy Growth (NYSE:CGC) has been building its CBD business, with a focus on consumer packaged goods. The company has since created a vertically integrated platform for that includes a set of technologies that have pending patents. What's more, the hemp division is expected to yield 7,000 kilos of hemp-derived CBD on an annual basis. Granted, this cannot be used in the U.S. market. Yet CGC is likely to be a solid partner. For example, the company recently struck a deal with Martha Stewart's Sequential Brands Group, so as to develop CBD remedies for pets.It helps that CGC has substantial resources, which came from a mega $4 billion investment from Constellation Brands (NYSE:STZ). STZ has a strong global footprint -- with operations in the U.S., Mexico, New Zealand, Italy and Canada -- as well as a set of well-known consumer brands, such as Corona Extra, Corona Light, Modelo Especial, Modelo Negra and Pacifico. All in all, there is quite a bit of synergy for CGC.In the meantime, the company is growing at a staggering pace. In the latest quarter, revenues soared by 282% to $83 million. GW Pharmaceuticals (GWPH)The origins of GW Pharmaceuticals (NASDAQ:GWPH) go back to 1998. It was then that Dr. Geoffrey Guy and Dr. Brian Whittle co-founded the company to focus on developing therapies using cannabinoid formulations to target areas like epilepsy, glioma and schizophrenia.As of today, the lead product is a liquid formulation of a CBD, called Epidiolex, which received FDA approval in 2018 (the expectation is that there will be an approval in Europe in the second quarter). The drug targets the rare conditions of Lennox-Gastaut syndrome (LGS) or Dravet syndrome, which are variations of epilepsy. Furthermore, there are other indications for Epidiolex, such as Tuberous Sclerosis Complex and Rett Syndrome. * 7 ETFs for a Millennial Portfolio But of course, the company has other treatments. Note that GWPH is looking to get approval in the U.S. for Sativex, which is an oromucosal spray for multiple sclerosis. It is currently available in 25 countries. Horizons Marijuana Life Sciences ETF (HMLSF)If you do not want to buy individual CBD stocks, then you can consider an exchange-traded fund, such as the Horizons Marijuana Life Sciences ETF (OTCMKTS:HMLSF). With this, you'll get exposure to companies like Canopy Growth, Aurora, GW Pharamceuticals, HEXO and Tilray (NASDAQ:TLRY).In all, there are 59 stocks in the portfolio and the net assets are about $1 billion (in Canadian currency). The expense ratio is also 0.75%.Tom Taulli is the author of High-Profit IPO Strategies, All About Commodities and All About Short Selling. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks That Will Continue to Rebound in 2019 * 5 Stocks To Buy for the Happiest Employees * 7 ETFs for a Millennial Portfolio Compare Brokers The post 7 Marijuana Stocks to Play the CBD Trend appeared first on InvestorPlace.
Top US Companies Impacted by Slowing European EconomyUS stock marketEarly on March 22, US stock indexes were trading on a negative note. On March 21, the stock indexes ended on a bullish note. On March 21, the S&P 500 Index, the NASDAQ
Procter & Gamble beat by a year its goal of delivering 15 billion liters of clean drinking water to needy people by 2020, and the company is now raising its target.
Kentucky Attorney General Andy Beshear said on Thursday he had launched an investigation into allegations that pharmacy benefit managers (PBMs) had overcharged state health insurance programs for drugs and discriminated against independent pharmacies. The investigation comes against the backdrop of widespread criticism of rising costs of prescription medicines in the United States, with PBMs, middlemen who negotiate prices for employers and health insurers, coming under intense scrutiny. Ohio's attorney general earlier this week sued UnitedHealth Group's OptumRx unit, which houses the largest U.S. health insurer's PBM business, to recover nearly $16 million in prescription drug overcharges.
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
What's Ahead for Church & Dwight and Clorox?(Continued from Prior Part)Valuation a concernThe majority of analysts covering Church & Dwight (CHD) and Clorox (CLX) stock maintain a neutral outlook despite better growth prospects among peers.
Positive development on the trade war front and the Fed???s dovish monetary stance are likely to be long-term catalysts for the blue-chip index.
The Dow Jones Industrial Average takes a fair amount of criticism from market pundits and financial experts. Some of that criticism is justified and often stems from just how the index its weighted. But you can't deny that the Dow Jones stocks are still some of the most important companies in the entire U.S. and overall world. With the thirty Dow Jones stocks being powerhouses in their respective fields, they feature enviable moats, large cash flows and big-time profits.And yes, stable and growing dividend payments.Overall, the Dow Jones stocks can be an income seeker's best friend. And just buying the index can lead to some good results. The index tracking SPDR Dow Jones Industrial Average ETF (NYSEARCA:DIA) pays a decent 2.25% yield. That's not too shabby at all. However, investors who are serious about finding more income need to dig deeper into Dow Jones stocks and take a look at individual names.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks on the Rise Heading Into the Second Quarter But which ones? Here are five of the best Dow Jones dividend stocks to buy today. Top Dow Jones Dividend Stocks: Cisco Systems (CSCO)Source: Shutterstock Dividend Yield: 2.63%Dow Jones stock Cisco Systems (NASDAQ:CSCO) is proof that old dogs can learn new tricks and that tech's elder statesmen still have plenty of growth behind them.After being the go-to networking firm during the dotcom days, CSCO switched gears to offer more services and other products to go along with their networking equipment. It turns out this was a great idea. Services revenues for the firm continue to surge. Even better is that subscriptions for software and services jumped to be 65% of Cisco's non-equipment revenues. These reoccurring revenues provide the firm with a long runway to keep growth going. And with reoccurring and services profit margins well into the double digits, Cisco has indeed been growing.The firm managed to see double-digit non-GAAP per share growth in the last quarter.And as expected, CSCO has been sharing its growth with shareholders. Since its first dividend payout in 2011, Cisco has upped its dividend by over 480%. That includes the 6% jump at the beginning of this year. This dividend growth rate puts the networking firm in very elite company among Dow Jones stocks.Add in its hefty buyback programs and continued revenue/cash flow growth, CSCO belongs in every income investor's portfolio. Pfizer (PFE)Source: Kojach Via FlickrDividend Yield: 3.45%Like Cisco, pharmaceutical firm Pfizer (NYSE:PFE) has been able to find growth and additional sources of revenue in recent years. Like many pharmaceuticals, PFE was facing a major patent cliff as several of its blockbusters -- such as Lipitor and Viagra -- went off patent. However, PFE was able to fill those holes with several other major product launches as well as targeting biosimilars and generic drugs. New cancer and recently launched biotech drugs have set the firm back on the path to growth once more. And with a robust pipeline, PFE should continue to shine in the future.And those drugs will get a chance to shine pretty bright thanks to a spin-off/merger.Pfizer already spun-out its slow-moving animal health division as Zoetis (NYSE:ZTS). However, the firm announced that it plans on merging its consumer health division with GlaxoSmithKline's (NYSE:GSK). The deal will push some of the boring and slow-growing pieces of its pie outwards and let the higher-margined drugs shine. This should strengthen its cash flows and dividends further. * 5 of the Best Stocks to Buy Under $10 And speaking of those dividends, PFE recently upped its payout by 5.88% on the back of robust cash flows and increased earnings from its new drugs. That dividend represents the company's 322 consecutive payout and its ninth year of annual dividend increases. Top Dow Jones Dividend Stocks: Chevron (CVX)Source: swong95765 via Flickr (Modified)Dividend Yield: 3.58%Big oil is a great place to find big dividends. That includes top Dow Jones stocks like Chevron (NYSE:CVX). CVX has long been a great place to find higher yields and more recently that yield has gotten better.Like many energy stocks, Chevron dug in deep and cut costs, reduced its drilling and focused on profitable long-term production efforts during the last oil rout. With many of these projects now starting to produce some hefty natural gas and oil, CAPEX spending at the oil giant has decreased. Meanwhile, higher overall oil prices have helped boost cash flows at the firm. All of which has made its dividend that much stronger.After several years of token dividend increases, CVX has finally gotten back to meaningful raises and upped its payout by 6.25% at the start of the year. Today, CVX yields a high 3.58%. That's all thanks to rising cash flows and better margins.Even better is that the firm has recently announced that it plans on doubling down its exposure to low-cost shale in the Permian Basin. Over the next four years, CVX plans on doubling its output in the region to more than 900,000 barrels per day. Given how juicy margins are in the shale, this will only help the firm and its investors further.After a rocky patch, Chevron is back on track to being one of the top Dow Jones stocks. Top Dow Jones Dividend Stocks: JPMorgan Chase & Co (JPM)Source: Shutterstock Dividend Yield: 3%When it comes to banks in the Dow Jones, JPMorgan (NYSE:JPM) can't be beaten. As the nation's largest bank, JPM features a huge competitive advantage, large moat and an asset base that only a few competitors can even come close to. And that base continues to get better.Last quarter, JPM managed to see its loans and deposits grow by 2% and 3%, respectively. Meanwhile, credit card sales jumped by 10% year-over-year. This is wonderful news for the bank. Banks like JPM profit from something called net-interest margins. Basically, it's the difference between what they charge on loans and what they hand back on deposits. With rates rising and the economy growing, this has been a boon to JPM's cash flows over the last year or so.Meanwhile, the firm continues to benefit from rising trading, asset management, corporate and high net worth/private banking growth. All of which has helped grow the bank at superb rates. Fellow InvestorPlace contributor Tom Taulli recently highlighted J.P. Morgan's amazing ability to generate strong returns on tangible common equity -- besting many of its peers by a wide margin. * 7 Video Game Stocks on Steep Discount With the bank trading at 3% yield and a forward price-to-earnings ratio of just 10, JPM is one heck of a bargain. And with its ability to generate strong returns and cash flows, income seekers should be snagging up shares of this Dow Jones stock with both hands. Top Dow Jones Dividend Stocks: Procter & Gamble (PG)Source: Mike Mozart via Flickr (Modified)Dividend Yield: 2.8%When it comes to Dow Jones stocks, boring can be beautiful. Consumer products giant Procter & Gamble (NYSE:PG) is a testament to that. Selling Crest toothpaste, Tide laundry soap and Bounty paper towels isn't a very exciting business, but it is stable. And over the decades, that stability has made PG a dividend machine. The firm has managed to raise its dividend for 62 consecutive years and currently offers a hefty 2.8% dividend yield.The best part is that PG has continued to try and improve its business and add some significant innovation to its portfolio.That turnaround is paying benefits in a big way. The firm has managed to pick up some meaningful market share versus rivals, with organic growth growing by over 4%. This was driven by product innovation and is now the second quarter of 4% organic growth. Meanwhile, cost cutting exercises and a lower overall tax rate helped boost margins to 22%. Overall, Procter & Gamble managed to crush expectations when it came to earnings-per-share. With the big beat, it helped cement that PG's turnaround is working.Also underscoring that fact further was Procter & Gamble's massive $4 billion in operating free cash flows.For investors, PG stock isn't insanely exciting, but it can provide a steady stream of dividend growth for years to come. And that makes it one of the best Dow Jones stocks for income seekers.At the time of this writing, Aaron Levitt did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Invincible Stocks Leading The Bull Market Higher * 5 Dow Jones Stocks Coming to Life * 7 of the Best High-Yield Funds for 2019 and Beyond Compare Brokers The post 5 of the Best Dow Jones Stocks to Buy for Solid Dividends appeared first on InvestorPlace.
Share are up 15% year to date, helped by the FDA’s acceptance of new applications for Botox. Still, questions remain about the health of the drugmaker’s pipeline and earnings profile.
March is winding down, and that means the end of the first quarter of 2019. The Q4 earnings season has all but wrapped up. So it's time to prepare for to the second quarter and take a look at some stocks on the rise now.Identifying those stocks is easier said than done though, particularly in this environment. The bulls are determined to hold onto the hard-won gains reaped since the late-December low, but it's becoming more and more difficult. The more the market goes up, the less the buyers are interested in buying in, and trading volume wanes.Nevertheless, there are some stocks on the rise and positioned to continue rallying into the foreseeable future. These names are a trader's best bet at what's often a modestly bullish time of year for the market.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 5 Cloud Stocks to Help Your Portfolio Fly With that as the backdrop, here's a rundown of the best stocks to buy as we enter Q2. Nielsen Holdings (NLSN)Yes, this is the same Nielsen Holdings (NYSE:NLSN) that measures viewership of television shows. It's more than that, however, the company also measures the efficacy of online and offline marketing campaigns.The past couple of years have been tough for shareholders. NLSN stock fell from a 2016 high near $56 to a mid-2018 low around $21. But the past few months have been progressive. Nielsen shares have recently broken through their 200-day moving average, and bullish crosses of other key moving-average lines are on the radar. Keep in mind, however, that we've seen this headfake before.This movement, along with the stock's forward P/E of 14.6 and the fact that it's going to begin quantifying data regarding Canada's cannabis industry, suddenly makes NLSN an interesting prospect. Amazon.com (AMZN)Like most other names, Amazon.com (NASDAQ:AMZN) stock was up-ended during Q4 of 2018. Unlike most other stocks, however, AMZN didn't produce the rip-roaring rally most other names did in January and February.That's changed this month. Despite the slow start to its rebound, AMZN stock is now on the rise. Shares just fought their way back above the pivotal 200-day moving average line, but have plenty more room to make gains.There's also plenty of bullish fodder, including the company's planned expansion of its grocery business and the ongoing growth of Amazon Web Services. * 4 Unexpected Trade War Stocks That Will Benefit From an End to Tariffs Fun fact: AMZN stock averages a 14% gain during the second calendar quarter of the year. TreeHouse Foods (THS)This stock is exactly a household name, but many households are regular users of its products without even realizing it. TreeHouse Foods (NYSE:THS) makes a variety of private-label foods sold by grocers and restaurants.TreeHouse Foods hasn't exactly been firing on all cylinders lately. The current quarter's per-share profits are projected to fall -- as are full-year sales.The company's fiscal results are poised to begin improving in the foreseeable future though, fueled by an industry-wide movement that puts even more focus on so-called 'house brands' of food and condiments. That's why investors have been willing to bid THS stock up nearly 65% since 2018's lows. And there's still a lot of opportunity for more gains thanks to THS stock's 2016/2017 meltdown. Align Technology (ALGN)Align Technology (NASDAQ:ALGN) is the company behind Invisalign's clear braces. Align has been successful for years, but found a sweet spot between price, demand and marketing beginning in 2016. From the end of 2015 to the middle of last year, ALGN stock gained more than 500%. * 7 Invincible Stocks Leading The Bull Market Higher That rally unraveled last year, with Align shares being chopped in half in the face of legal woes surrounding certain patents on its technology… a matter that's still not been firmly decided. Investors are regaining confidence in the company's prospects though. Up more than 40% above its early January low, Align is one of a handful of stocks on the rise moving into Q2. Century Aluminum (CENX)Despite respectable economic growth for the past year and a half, aluminum prices have been falling. Indeed, over the past twelve months, the price of aluminum is down roughly 13%, and still in position to edge lower.It's taken a toll on most of the industry's stocks, including Century Aluminum (NASDAQ:CENX). But, CENX may be on the verge of a turnaround. It's just crossed above several key moving averages, and those moving average lines have just dished out bullish crosses of their own.It also helps to know that Century Aluminum shares, like aluminum prices, have been reliably cyclical. The current shift out of a downtrend and testing the waters of an uptrend looks an awful lot like the rebounds we saw in 2016 and 2013. Pentair (PNR)London-based Pentair (NYSE:PNR) makes a variety of 'smart water' solutions, ranging from pumps to filters to agricultural applications.It's not a high-growth business, but it is a reliably profitable business, even if those profits can be a bit uneven at times. * 7 Financial Stocks to Invest In Today Butt his year should be a decent one. Revenue is projected to improve by 5.3%, and per-shares profits are expected to reach $2.55 -- up from last year's $2.35. That progress has translated into new bullishness for PNR shares too. After a hard reversal near the end of 2018, Pentair stock is finally toying with highs above its technical ceiling at $43.60. Cabot Oil & Gas (COG)Energy stocks are inherently volatile, even more so in the current environment. But after tumbling in Q4 alongside falling crude prices, they're looking like good bets again.Cabot Oil & Gas (NYSE:COG) is shaping up to one of the top prospects from the energy sector. Investors have to zoom out to a weekly chart to fully appreciate it, but shares have slowly shifted out of a downtrend and into an uptrend over the course of the past several months. One more good gain could complete the breakout effort, which has pushed COG stock past all key moving averages.The kicker: COG averages a Q2 gain of 7.4%. Allergan (AGN)Allergan (NYSE:AGN) has been a poor performer since peaking in the middle of 2015. In fact, AGN stock is down more than 50% from that high, and hit a new 52-week low in December. It's been a challenging name to own, to say the least. * 5 Dow Jones Stocks Coming to Life Yet, a shocking number of hedge funds and institutional investors now own a beaten-down Allergan. As Sanford C. Bernstein's pharmaceutical analyst Ronny Gal explained last month, Allergan has become a very popular holding, partially because it has buyout potential and partially because the company is just doing well. Additionally, Gal is excited about the value creation that could stem from an increasingly likely breakup of Allergan's different arms. Molson Coors Brewing (TAP)Molson Coors Brewing (NYSE:TAP) has been in a downtrend since the middle of 2016 and reached new multi-year lows in December of last year. TAP stock has been toying with a reversal since October though -- an effort marked by a lot of volatility and several big countermoves. The bulls are testing the waters, even if they're not making a lot of not progress. But one more good 'umph' could get -- and keep -- TAP shares above key moving averages and break through the technical ceiling that's formed near $67.00.The calendar is working in TAP stock's favor as well. Molson Coors shares gain an average of 3% during Q2, but keep on moving through September to log an and additional average gain of about 4% during Q3. Old Republic International (ORI)Finally, add Old Republic International (NYSE:ORI) to your list stocks on the rise as the Q2 begins.Like most insurance stocks, ORI has had its recent ups and downs. Unlike most of its peers though, Old Republic is making reliable net progress, taking two steps forward for every one step back. ORI has been weak since September, but appears to be pushing off of a support line that extends all the way back to early 2015. * Top 7 Service Sector Stocks That Will Pay You to Own Them Analysts agree there are higher highs in store. Although ORI is not widely followed by professionals, the ones that do keep tabs on it collectively say the stock's worth $24 per share, which would put it near the upper boundary of the trading range that's been in place since 2015.As of this writing, James Brumley held a long position in Treehouse Foods and Nielsen Holdings . You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Invincible Stocks Leading The Bull Market Higher * 5 Dow Jones Stocks Coming to Life * 7 of the Best High-Yield Funds for 2019 and Beyond Compare Brokers The post 10 Stocks on the Rise Heading Into the Second Quarter appeared first on InvestorPlace.
WellCare Health (WCG) unit introduces a unique mobile app, Atlas Compass, to assist PBM members to manage their pharmacy health information.
What's Ahead for Church & Dwight and Clorox?(Continued from Prior Part)Top line to sustain momentum Clorox (CLX) could continue to report healthy sales growth despite pressure on net sales from currency volatility. Management expects its top
Conatus (CNAT) concentrates on the development of its lead candidate, emricasan, for treating patients with fibrosis or cirrhosis caused by NASH.
Riding high on solid segmental performances, Universal Health (UHS) promises to reap great benefits for investors. However, its debt load bothers.
What's Ahead for Church & Dwight and Clorox?(Continued from Prior Part)CHD’s top line could continue to grow Church & Dwight (CHD) has impressed investors with its stellar sales performance in the recent past. The company’s top line has
Service Corp. (SCI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The S&P 500 and Dow rose and then reversed course to end lower after the Federal Reserve on Wednesday announced it was holding benchmark interest rates at current levels and signaled no further rate hikes in 2019.